Deramciclane in the treatment of generalized anxiety disorder: A placebo-controlled, double-blind, dose-finding study

@article{Naukkarinen2005DeramciclaneIT,
  title={Deramciclane in the treatment of generalized anxiety disorder: A placebo-controlled, double-blind, dose-finding study},
  author={H. Naukkarinen and Roope Raassina and J. Penttinen and A. Ahokas and R. Jokinen and H. Koponen and U. Lepola and H. Kanerva and Leena Lehtonen and T. Pohjalainen and Auli Partanen and O. M{\"a}ki-Ikola and J. Rouru},
  journal={European Neuropsychopharmacology},
  year={2005},
  volume={15},
  pages={617-623}
}
Deramciclane, a camphor derivative, is a novel anxiolytic agent with a unique mechanism of action. It acts as a potent and specific antagonist at serotonin 5-HT2A/2C receptors, and exhibits anxiolytic efficacy in animal models. The aim of this double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of a range of doses of deramciclane in patients with generalized anxiety disorder (GAD). Adult patients with a diagnosis of GAD (DSM-IV) and a… Expand
Non-Antidepressant Treatment of Generalized Anxiety Disorder.
TLDR
Pregabalin and quetiapine are the two most promising non-antidepressant treatments for GAD. Expand
Effect of the novel anxiolytic drug deramciclane on cytochrome P450 2D6 activity as measured by desipramine pharmacokinetics
TLDR
Although deramciclane seems to be a weaker inhibitor of CYP2D6 than paroxetine, dose adjustment of drugs metabolized by CYP 2D6 may be needed when used concomitantly with deram ciclane. Expand
Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone
TLDR
Deramciclane does not inhibit CYP3A4 activity as measured by buspirone pharmacokinetics, and there were no indications of relevant pharmacodynamic interaction after multiple doses of deramcIClane and a single dose of buspir one. Expand
Research in anxiety disorders: From the bench to the bedside
TLDR
Findings from a range of research strategies in anxiety are discussed, with particular reference to drugs modulating serotonergic, noradrenergic and gabaergic mechanisms and novel targets including glutamate, CCK, NPY, adenosine and AVP. Expand
Chapter 5.2 How effective are current drug treatments for anxiety disorders, and how could they be improved?
Abstract Although there are many psychotropic drugs and psychotherapies available for the treatment of patients with anxiety disorders, overall clinical outcomes and the standard of care for mostExpand
Agomelatine improves symptoms of generalised anxiety disorder
TLDR
Primary outcome: overall anxiety (HAM-A). Secondary outcomes: response (?50% reduction in HAM-A score) and discontinuation effects in the week after discontinuation (Discontinuation Emergent Signs and Symptoms scale (DESS). Expand
Advances in the Management of Treatment-Resistant Anxiety Disorders
Anxiety disorders are among the most common and disabling mental illnesses. While effective treatments exist, many patients—possibly even 50–60%—remain symptomatic despite first-line treatments. WithExpand
Current animal models of anxiety, anxiety disorders, and anxiolytic drugs
TLDR
It is shown that there is a large interest in performing anxiety research innovatively, however, efforts are highly divergent and result in large numbers of poorly validated and infrequently used novel approaches. Expand
Recent developments in anxiety disorders.
TLDR
The areas of current interest and possible future development of anxiolytic drugs by outlining recent patents in this field are described and grouped into neurotransmitter systems for an overview of recent developments in the neuropharmacology of anxiety disorders. Expand
Identifying HAM‐A cutoffs for mild, moderate, and severe generalized anxiety disorder
TLDR
The proposed cutoffs for mild, moderate, and severe ranges of Hamilton Anxiety Rating Scale (HAM‐A) scores could make results more meaningful and interpretable for researchers, clinicians, and patients if accepted for general use. Expand
...
1
2
...

References

SHOWING 1-10 OF 28 REFERENCES
Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
TLDR
Paroxetine in doses of 20 to 50 mg once daily is effective in the treatment of patients with GAD and is associated with significant reduction in disability after only 8 weeks of treatment. Expand
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
TLDR
Venlafaxine XR is an effective, safe, and well-tolerated once-daily anxiolytic agent in patients with GAD without comorbid major depressive disorder. Expand
Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
  • D. Sheehan
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2001
TLDR
The results of these studies demonstrate the strong potential of venlafaxine XR in facilitating remission in GAD, with a substantial effect size in the individual HAM-A items of worry, anxiety, and behavior at interview. Expand
Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.
TLDR
In generalized anxiety, somatic symptoms and hyperarousal selectively respond to drugs acting on the gamma-aminobutyric acid system, whereas psychic symptoms respond to treatments affecting the noradrenergic or serotonergic systems. Expand
Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.
TLDR
The HAM-A and BSA items that most closely corresponded to DSM-IV diagnostic criteria for GAD showed the largest improvement during treatment with venlafaxine XR, indicating that the specific symptoms of GAD can be treated effectively with ven lafaxines extended release, both in the short and longer term. Expand
Paroxetine efficacy in the treatment of generalized anxiety disorder
TLDR
Paroxetine and imipramine affect predominantly psychic symptoms, whereas 2′‐chlordesmethyldiazepam affects predominantly somatic symptoms, and the results suggest that paroxetines is effective for the treatment of GAD. Expand
Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone.
TLDR
Analysis of data for 427 patients with generalized anxiety disorders analyzed retrospectively from six double-blind trials indicated that all of the 14 symptom groups, the total HAM-A score, and the 2 composite Psychic and Somatic Anxiety Factors were significantly improved with buspirone as compared to placebo. Expand
Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.
TLDR
Although only wider clinical use for longer periods of time will more clearly define some elements of its pharmacological profile, with its low incidence of sedation buspirone is a useful addition to the treatments available for generalised anxiety. Expand
Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder
TLDR
All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses, and the discontinuation rate did not differ significantly among the treatment groups. Expand
Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder.
  • J. Ballenger
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2001
TLDR
Preclinical and clinical data supporting the role of GABA, 5-HT, and NE in the pathophysiology of GAD and the pharmacotherapeutic agents that modulate these neurotransmitter systems and have been proved efficacious in reducing the symptoms associated with GAD are summarized. Expand
...
1
2
3
...